Innate Pharma
Tracked across 5 events · 35 articles · First seen Apr 02, 2026 · Last active Aug 10, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: Innate Pharma filed its 2025 Universal Registration Document and Form 20-F annual report, fulfilling regulatory obligations for publicly traded companies.
Apr 02, 2026 · 7 articles
Business
Impact: Innate Pharma will present its oncology pipeline and strategies at the AACR Oncology Industry Partnering Event, providing an opportunity to attract investors and accelerate therapy development.
Apr 08, 2026 · 6 articles
Regulatory
Impact: Innate Pharma released its total number of shares outstanding and voting rights as of April 9, 2026, in compliance with French regulatory requirements.
Apr 13, 2026 · 6 articles
Business
Impact: Innate Pharma announced the voting results of its Annual General Meeting, which is a routine corporate governance event. The event confirms the company's adherence to regulatory requirements and shareholder engagement.
May 22, 2026 · 6 articles
Business
Impact: Innate receives $75 million upfront and up to $505 million in milestones plus royalties, funding its Phase 3 trial and providing validation for its pipeline.
Aug 10, 2026 · 10 articles
ERGEN INTELLIGENCE
Track Innate Pharma live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard